Status:
UNKNOWN
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Conditions:
Leukemia
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination c...
Detailed Description
OBJECTIVES: * Determine the dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of doxorubicin hydrochloride in pediatric patients with acute lymphoblastic leukemia (ALL). * Determine w...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosed with acute B-precursor or T-cell acute lymphoblastic leukemia (ALL)
- Meets 1 of the following risk criteria:
- Low-risk disease, defined by any of the following:
- WBC \< 25/nL
- B-precursor ALL
- Excluding pro-B ALL
- High-risk disease, defined by any of the following:
- WBC ≥ 25/nL
- T-cell ALL or pro-B ALL
- Chromosomal translocation 4/11
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- More than 7 days since prior therapy with steroids, vincristine, or daunorubicin hydrochloride
- More than 7 days since prior cytotoxic therapy
Exclusion
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT00343369
Start Date
January 1 2003
Last Update
August 26 2013
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Evangelisches Krankenhauus Bielfeld
Biefeld, Germany, 33617
2
Klinikum Bremen-Mitte
Bremen, Germany, D-28205
3
Universitaetsklinikum Duesseldorf
Düsseldorf, Germany, D-40225
4
Universitats - Kinderklinik
Greiswald, Germany, 17487